ERBB2 and breast carcinoma: We assayed 294 primary breast cancer tissue samples from 111 patients with primary ER+/HER2-negative breast cancer who participated in the neoadjuvant PELOPS, including samples from baseline, on treatment (day 15), and surgery time points (Fig. 1A).